Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab in High-Risk Smoldering Multiple Myeloma
NCT05955508Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Jan 2033
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of linvoseltamab in smoldering multiple myeloma (SMM), sponsored by Regeneron Pharmaceuticals. Started Jan 2024; status: active, not recruiting.
02
Drugs
linvoseltamab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05955508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955508.